Search
Xintiandi (301277.SZ) has announced the acquisition of the "Drug Registration Certificate" for Vildagliptin Tablets from the National Medical Products Administration, classifying the drug under Category 4 of chemical medications. This certification signifies that Vildagliptin Tablets have successfully passed the consistency evaluation, granting Xintiandi the authorization to manufacture and market the drug within the domestic realm. This milestone not only augments the company's product portfolio but is also anticipated to bolster its market competitiveness. Nevertheless, the exact timing of market launch and sales performance remain uncertain, and Xintiandi vows to adhere to regulatory requirements in fulfilling its information disclosure obligations.
-
C114 Communication Network -
Communication Home
